In Reply Our Viewpoint1 summarized animal studies with respect to the association of cyclooxygenase (COX) 2 and prostaglandin-E2 (PGE2) disruption with neurodevelopment, including the use of COX inhibitors such as aspirin or indomethacin.1 Relevant research needs to be introduced in pediatric clinical discussions and warrants future neurobehavioral studies, especially because clinical data will probably lead to (1) treatment of considerably more pregnant women (almost 11% of total) at high risk for preeclampsia with low-dose aspirin (LDA) and (2) increased and prolonged fetal exposure to aspirin.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Voutetakis A, Pervanidou P, Kanaka-Gantenbein C. Vital Considerations for Aspirin in Prevention of Preeclampsia, a Multifaceted Pregnancy Disorder—Reply. JAMA Pediatr. Published online November 04, 2019. doi:https://doi.org/10.1001/jamapediatrics.2019.4021
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: